Shares of biotech BioMarin (NASDAQ:BMRN) spiked more than 20% today in pre-market trading after the company released exciting data from its Mucopolysaccharidosis Type IVA (or MPS IVA) clinical trial. Although this company boasts a market cap close to $6 billion, it might fly under the radar for some investors. What does this company focus on, and what should investors be watching for the long term?
BioMarin is a biopharmaceutical company that focuses on serious rare diseases, which means that the company's portfolio and pipeline have more orphans than a Charles Dickens collection. Treatments for rare diseases are often called "orphan drugs," and, in addition to potentially helping patients, this is a growing business for BioMarin. Its year-over-year net loss in the third quarter shrank from $17.7 million to $5.4 million. Revenue also grew 13% to reach $128.1 million.
Let's take a closer look at what BioMarin needs to do to maintain its positive momentum.
BioMarin has four treatments available on the market, and the combined improved earnings, year-over-year, is what drove up overall revenues for the quarter.
Naglazyme is the biggest seller, reporting $62.5 million in revenue in the third quarter, an increase of 12%. Naglazyme treats mucopolysaccharidosis VI (MPS VI), a potentially fatal genetic deficiency of a lysosomal enzyme. MPS VI is estimated to occur in between 1 in 250,000 and 1 in 600,000 births.
Kuvan -- a treatment for the genetic metabolic disorder phenylketonuria, or PKU -- rose 19% to $36.4 million. PKU results in dangerously high levels of the amino acid phenylalanine and can lead to devastating neurological impairments. It's estimated that there are 14,500 people in the U.S. with PKU.
BioMarin manufactures the orphan drug Aldurazyme but leaves the domestic and international commercialization to Genzyme, a Sanofi (NYSE:SNY) subsidiary. Aldurazyme treats MPS I, a potentially fatal enzyme disorder. The drug had net profits for BioMarin totaling $23.8 million, up 3.5% on the year.
Trailing behind in fourth place is Firdapse with $3.6 million, an increase of 2.9%. Firdapse treats Lambert-Eaton myasthenic syndrome, or LEMS, a rare autoimmune disease that frequently presents with a second condition, such as cancer. Firdapse is available in the EU but is still going through the approval process in the United States.
Although the patient populations for these drugs are small, BioMarin has the benefit of having the only treatments currently available. Revenues would be damaged by a competitor bringing out a drug that at least matches, if not exceeds, the efficacy of BioMarin's products.
It's mostly quiet on the competition front. Zacharon Pharmaceuticals is a development partner with Pfizer (NYSE:PFE) for the creation of MPS I, II, and III treatments, potentially creating a competitor for Adurazyme. But that project hasn't yet produced a clinical candidate.
An increasing number of big pharma companies are moving into orphan territory, but the ultra-orphan status of many of the conditions that BioMarin covers may keep the big boys away for the most part.
BioMarin's pipeline isn't enormous, but it has a couple of strong contenders moving toward late stages.
One of the most anticipated is the GALNS drug for MPS IVA. Phase 3 trial results were reported today, and the successful results from this study sent the stock soaring.
Following close behind on the advancement trail is the PKU treatment PEG-PAL. There will be an end of phase 2 meeting with the FDA in the first quarter of next year, and phase 3 should start in the second quarter.
After today's share price surge, BioMarin is trading at about 60% above its 52-week low and is up nearly 40% year to date. The company has a solid set of products on the market that are showing at least modest revenue increases. The GALNS trial result was a major catalyst today, but investors still need to keep an eye on BioMarin's sales and progress in commercializing the drugs in its pipeline.
Fool contributor Brandy Betz has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend BioMarin Pharmaceutical. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why This Gene Therapy Pioneer Crashed 29.8% in December
Progress toward commercializing its first gene therapy failed to overcome concern about competition last month.
5 Biotech Buyout Candidates for 2018
The Republican-inspired U.S. tax reform could spur an acquisition bonanza in biotech next year. Here's a look at five companies that might be prime targets.
BioMarin Pharmaceutical Inc. on Target for Its 15% Revenue Growth Goal
The biotech keeps plugging along.